Literature DB >> 20956342

Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting.

Merav Cohen1, Moshe Elkabets, Michal Perlmutter, Angel Porgador, Elena Voronov, Ron N Apte, Rachel G Lichtenstein.   

Abstract

Sialylation of tumor cells is involved in various aspects of their malignancy (proliferation, motility, invasion, and metastasis); however, its effect on the process of immunoediting that affects tumor cell immunogenicity has not been studied. We have shown that in mice with impaired immunoediting, such as in IL-1α(-/-) and IFNγ(-/-) mice, 3-methylcholanthrene-induced fibrosarcoma cells are immunogenic and concomitantly bear low levels of surface sialylation, whereas tumor cells derived from wild type mice are nonimmunogenic and bear higher levels of surface sialylation. To study immune mechanisms whose interaction with tumor cells involves surface sialic acid residues, we used highly sialylated 3-methylcholanthrene-induced nonimmunogenic fibrosarcoma cell lines from wild type mice, which were treated with sialidase to mimic immunogenic tumor cell variants. In vivo and in vitro experiments revealed that desialylation of tumor cells reduced their growth and induced cytotoxicity by NK cells. Moreover, sialidase-treated tumor cells better activated NK cells for IFN-γ secretion. The NKG2D-activating receptor on NK cells was shown to be involved in interactions with desialylated ligands on tumor cells, the nature of which is still not known. Thus, the degree of sialylation on tumor cells, which is selected during the process of immunoediting, has possibly evolved as an important mechanism of tumor cells with low intrinsic immunogenicity or select for tumor cells that can evade the immune system or subvert its function. When immunoediting is impaired, such as in IFN-γ(-/-) and IL-1α(-/-) mice, the overt tumor consists of desialylayed tumor cells that interact better with immunosurveillance cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956342     DOI: 10.4049/jimmunol.1001635

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Authors:  Camilla Jandus; Kayluz Frias Boligan; Obinna Chijioke; He Liu; Meike Dahlhaus; Thomas Démoulins; Christoph Schneider; Marc Wehrli; Robert E Hunger; Gabriela M Baerlocher; Hans-Uwe Simon; Pedro Romero; Christian Münz; Stephan von Gunten
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 2.  Two opposing roles of O-glycans in tumor metastasis.

Authors:  Shigeru Tsuboi; Shingo Hatakeyama; Chikara Ohyama; Minoru Fukuda
Journal:  Trends Mol Med       Date:  2012-03-16       Impact factor: 11.951

3.  A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.

Authors:  Sarah Abdullahi; Melanie Jäkel; Sabine J Behrend; Katja Steiger; Geoffrey Topping; Teresa Krabbe; Alessio Colombo; Volker Sandig; Tobias S Schiergens; Wolfgang E Thasler; Jens Werner; Stefan F Lichtenthaler; Roland M Schmid; Oliver Ebert; Jennifer Altomonte
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

4.  Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Authors:  Michal A Stanczak; Shoib S Siddiqui; Marcel P Trefny; Daniela S Thommen; Kayluz Frias Boligan; Stephan von Gunten; Alexandar Tzankov; Lothar Tietze; Didier Lardinois; Viola Heinzelmann-Schwarz; Michael von Bergwelt-Baildon; Wu Zhang; Heinz-Josef Lenz; Younghun Han; Christopher I Amos; Mohammedyaseen Syedbasha; Adrian Egli; Frank Stenner; Daniel E Speiser; Ajit Varki; Alfred Zippelius; Heinz Läubli
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

5.  Cutting back on the carbs.

Authors:  Vivian H Trang; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-01       Impact factor: 11.205

6.  Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation.

Authors:  Christian Büll; Estel Collado-Camps; Esther D Kers-Rebel; Torben Heise; Jonas N Søndergaard; Martijn H den Brok; Barbara M Schulte; Thomas J Boltje; Gosse J Adema
Journal:  Immunol Cell Biol       Date:  2016-11-22       Impact factor: 5.126

Review 7.  Enzymes as Immunotherapeutics.

Authors:  Shaheen A Farhadi; Evelyn Bracho-Sanchez; Sabrina L Freeman; Benjamin G Keselowsky; Gregory A Hudalla
Journal:  Bioconjug Chem       Date:  2018-01-31       Impact factor: 4.774

8.  Precision glycocalyx editing as a strategy for cancer immunotherapy.

Authors:  Han Xiao; Elliot C Woods; Petar Vukojicic; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

Review 9.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 10.  Glycobiology of cell death: when glycans and lectins govern cell fate.

Authors:  R G Lichtenstein; G A Rabinovich
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.